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Introduction
G protein-coupled receptor (GPCR) genes belong to a family that have been exploited extensively as drug targets. Masrelated genes (Mrgs) are recently identified GPCR family genes (Dong et al., 2001 , Choi and Lahn, 2003 , Vassilatis et al., 2003 , Zhang et al., 2005 . The Mrg gene family has 32 murine and 4-7 human genes (hMrgX1-hMrgX7) (Vassilatis et al., 2003) . Interestingly, the mRNAs of Mrgs are expressed predominantly in non-overlapping subsets of non-peptidergic neurons in the dorsal root ganglia (DRGs) and trigeminal ganglia (TRGs) (Dong et al., 2001, Choi and Lahn, 2003) . They are expressed only in the nociceptive neurons of these sensory ganglia. This specific expression pattern may imply their significant roles in the physiological and pharmaceutical aspects of pain processing.
System biology, biochemical and immunological studies indicate the amazing complexity of the mechanism of action of interaction peptides. Mrg genes respond to many biogenic amines and peptides. Agonist binding to these receptors initiates various G-protein-mediated intracellular reactions such as modulation of adenylate cyclase or Ca 2+ mobilization (Okayama et al., 2008 , Siehler et al., 2008 , Aicher et al., 2009 , Subramanian et al., 2011a . Bio-informatic and tissue distribution analysis have been used to identify cognate and surrogate ligands. The orphan receptor gene MrgX2 is a member of the Mrg gene family that is related to the Mas1 oncogene (Robas et al., 2003 , Allia et al., 2005 , Kamohara et al., 2005 , Akuzawa et al., 2009 , Kashem et al., 2011 , Subramanian et al., 2011a .
The Mrg gene family has been found to undergo strong Darwinian positive selection in mammalian species (Choi and Lahn, 2003 , Tominaga et al., 2003 , Tominaga et al., 2005 , Zhang et al., 2005 , Burstein et al., 2006 . Thus, its role in the adaptive evolution of the pain-perception-related nervous system and immune system functions could be focused in future. Nevertheless, their detailed functions and the relative mechanisms of signal transduction are still not well understood (Choi and Lahn, 2003 , Zhang et al., 2005 , Burstein et al., 2006 .
Study on Mrgs is a new research field and will help researchers to understand pain mechanisms, nociceptor development and immune system functions. It may also contribute to new targeted drugs development. As a newly evolved family member, human MrgX2 may play a role in the evolution of the human nervous system and is very important to mast cells. The aim of this article was to review the recent progress in research on the gene MrgX2, including its origin, expression, functions and future research foci.
The location, evolution and future research focus of MrgX2

The location of MrgX2
Human MrgX2 gene is a two-exon gene located on chromosome 11p15 and encoding a protein with 330 amino acids. Data on MrgX2 chromosomal location in other primates were shown in Table 1 . With the completion of the human genome project, hundreds of orphan GPCRs have been reported (Choi and Lahn, 2003) .
Rapid evolution of Human MrgX2 (hMrgX2)
It has been reported that all human MrgX genes are closely related to each other and this result is from recent gene duplications that postdate primate-rodent divergence (Burstein et al., 2006) . Yang et al. (Yang et al., 2005) sequenced the MrgX2 gene in world-wide human populations and primate species. Their studies on DNA polymorphism patterns showed an excess of derived substitutions, implying the occurrence of adaptive evolution of MrgX2 in human (Yang et al., 2005) . Three of the four human-specific amino acid substitutions were located extra-cellularly, which is important for the interaction with ligands, potentially leading to adaptive changes in the pain-perception-related nervous system or mast cell migration activities during human evolution (Yang et al., 2005) . All these results demonstrated a strong Darwinian positive selection in humans, which may contribute to adaptive changes of the sensory system or immune system during human evolution (Yang et al., 2005 , Zhang et al., 2005 .
Future research focus of MrgX2
It is still unclear why rapid mutation of MrgX2 occurred in human and what this rapid evolution implies. An evolutionary functional analysis of the mutants probably need to be performed to understand the Darwinian rapid evolution of MrgX2. MrgX2 ancient sequences in primates can be obtained by the ancient sequence reconstruction method. Cell lines such as HEK293 can be used to determine the different mutation types of human MrgX2. The ancestor mutant genes along primate evolution help to understand the role of MrgX2 in the defense against microorganisms and pain modulation of sensory neurons. The calcium mobilization, degranulation and chemotaxis assays maybe help to understand the mutant meaning of the gene in the human beings. The evolutionary meaning of the mutations in human and other primates might help us to understand MrgX2 and even the Mrg gene family. In addition, the functional evolutionary analysis and mechanism of pain modulation of MRG proteins, as well as its functions in mast cells, would be important to understand the evolution of the primate and even mammalian nervous system and immune system. This would also be helpful for the development of drugs to alleviate pain, combat cancer and microbial infections. In our opinion, the immune driving force could cause mutations and lead to specific anti-microbial actions or immune activity adjustments. In this regard, MrgX2 signaling and regulation in mast cells might become a future research focus.
The expression pattern of MrgX2
A subgroup of receptors (MRGX1-MRGX4) is expressed in human but not murine neurons. Immuno-histochemical studies have been carried out in various normal and diseased human tissues and the results were summarized in Table 2 . MRGX2 has a limited expression profile in both the peripheral and central nervous system, being most abundant in DRGs and TRGs (Robas et al., 2003) . Quantitative polymerase chain reaction (PCR) data has confirmed that the highest levels of MrgX2 were observed in lumbar DRGs but high transcript levels were also seen in DRGs isolated from thoracic and cervical regions. These receptors were specifically found in the small-sized sensory neurons of DRGs and TRGs that are thought to be involved in the sensation and modulation of pain. Analysis of MRGX2 expression by immunohistochemistry in prostate samples revealed prominent staining of MRGX2 in the glandular epithelium whereas the fibromuscular stroma stained only faintly (Aicher et al., 2009 ). In contrast, tissues from benign prostatic hyperplasia exhibited only a slight increase in staining in the glandular epithelium but very prominent staining in the fibromuscular stroma (Choi and Lahn, 2003) .
MRGX2 was also expressed in human mast cells, including skin mast cells, cord blood-derived mast cells, CD34 + cellderived mast cells, compound 48/80 activated transfected mast cells and a mast cell line LAD2 (Subramanian et al., Subramanian et al., Tatemoto et al., 2006 , Okayama et al., 2008 , Niyonsaba et al., 2010 , Kashem et al., 2011 , Subramanian et al., 2013 . Interestingly, this receptor is only present in mast cells, but not other 41 human cell types examined, e.g. lymph nodes, spleen, peripheral blood leukocytes, etc. In addition, LAD2 and CD34 + cell-derived primary human mast cells express functional MRGX1 and MRGX2, but the immature human mast cell line HMC-1 does not (Subramanian et al., 2011a , Subramanian et al., 2011b , Subramanian et al., 2013 . Rat basophilic leukemia cell line RBL-2H3 and murine BMMCs do not express MRGX2 either. However, it may prove challenging to use an animal model to define the physiological effects of MRGX2 activation since studies have shown no mouse or rat orthologues of MrgX2.
The specific expression pattern of MrgX2 in mast cells suggests its importance in inducing degranulation or other important functions. Microarray expression data of primates, especially that of human, are appearing rapidly in the literature. The difference in expression of MrgX2 between patients with specific immune diseases and normal people may be analyzed by data mining.
Interaction of MRGX2 with peptide factors
Peptides known to activate human MRGX2 can be activated in the corresponding rhesus ortholog using GTP-gS-binding assays. The results were sumarized in Table 3 .
Substance P and vasoactive intestinal peptide activate MRGX2
Substance P and vasoactive intestinal peptide could activate MRGX2 (Zhang et al., 2005) . In the case of macaque MRGX2, its expression was co-localized with the known nociceptive neuronal markers IB4, VR1, Substance P and vasoactive intestinal peptide (Zhang et al., 2005) , suggesting that MRGX2 is involved in the modulation of nociception and contributes to the late-phase reaction of allergy.
With regard to allergy reaction, Fujisawa et al. (Fujisawa et al., 2014) found that it was significantly more intense and long-lasting in patients with chronic urticaria, and their mast cells expressed more MRGX2 than that of normal people. The percentage of MRGX2-positive skin mast cells and MRGX2-positive mast cells in patients with chronic urticaria were significantly greater than those in non-chronic urticaria subjects. Thus, MRGX2 may be the receptor of mast cells that contributes to the late-phase reaction of allergy.
Cortistatin (CST), proadrenomedullin N-terminal peptide (PAMP), Dextrorphan and 3-methoxy morphanin activate MRGX2
In human, CST is a cyclic peptide derived from a pre-propeptide of 114 residues and has been shown to play a role in the induction of slow wave sleep and inhibition of locomotor activity and cell proliferation (Rubinfeld and Shimon, 2006 , Broglio et al., 2007 , Broglio et al., 2008 , Gahete et al., 2008 , Siehler et al., 2008 , Van Hagen et al., 2008 , Volante et al., 2008 , Baranowska et al., 2009 . Small molecules, peptides and bioactive lipids, e.g. CST-14 and -17, contain both the N-terminal proline and the C-terminal lysine amide, exhibit high affinity for MRGX2, and may activate GPCR. Overlapping distribution of MRGX2 and CST was seen in DRGs, testis and pancreas (Allia et al., 2005) .
Recently, PAMP (Kamohara et al., 2005) , especially the PAMP-12, were identified as endogenous ligands for MRGX2. Ligands of MRGX2 have been screened using an MRGX2-G ␣i fusion protein expressed by Sf 9 cells (Subramanian et al., 2011a) , demonstrating that MRGX2 is a G ␣i/o protein-coupled receptor activated by PAMP.
Dextrorphan and 3-methoxy morphanin, which are morphine analogs, are also found to partially activate MRGX2 (Tanaka et al., 2003) . MRGX2-expressing cells were stimulated not only by CST and PAMP, but also by morphine and its derivatives excluding leucine-enkephalin and ␣-endorphin (Subramanian et al., 2011a , Subramanian et al., 2011b , Subramanian et al., 2013 .
LL-37 activates MRGX2
LL-37 belongs to a group of antimicrobial peptide gene family cathelicidins, with some members having pleiotropic effects in addition to their antibacterial, antifungal and antiviral activities. They also exhibit chemotactic and immuno modulatory functions (Niyonsaba et al., 2001 , Niyonsaba et al., 2003 . Furthermore, they are involved in wound healing, angiogenesis and apoptotic pathway. Recent analysis indicated that they also participate in cancer (Niyonsaba et al., 2010) . MRGX2 is a molecular target of LL-37. Through various inflammatory signaling pathways, MRGX2 could be activated or modulated by LL-37, resulting in inflammatory responses by activating cytoplasmic targets to release cytokines, control cell motility, and cause cell proliferation (Subramanian et al., 2011a , Vandamme et al., 2012 .
LL-37 interacts with the G i protein-coupled receptor MRGX2 on mast cells. Furthermore, the experimental results from knockdown of MrgX2 in human mast cells has shown that LL-37 induces sustained Ca 2+ mobilization and degranulation via MRGX2. Moreover, LL-37 promotes chemotaxis and induces chemokine CCL4 via MRGX2 in transfected mast cell lines (Subramanian et al., 2011a) .
Although MRGX2 has been identified as a key receptor of LL-37 on mast cells, other unidentified GPCRs have also been proposed as receptors for LL-37 (Lau et al., 2005 , Lau et al., 2006 and implicated in LL-37-mediated modulation of DC differentiation. Based on inhibition of LL-37-mediated effects by pertussis toxin, Davidson (Davidson et al., 2004) showed that LL-37 could cause chemotaxis, degranulation and chemokine production in human mast cells, but it could not induce receptor desensitization.
PMX-53 may activates human mast cells via MRGX2
It is currently unknown whether this receptor is activated by endogenous peptides produced in the context of innate immunity and inflammation. However, human defensins, which are amphiphilic peptides, induce mast cell degranulation at concentrations similar to those observed for PMX-53 (Subramanian et al., 2011b) . Defensins produced by epithelial cells during microbial infection may activate human mast cells via MRGX2 to promote innate immunity. It is possible, therefore, that the dual effect of PMX-53 could be pharmacologically relevant in promoting both anti-inflammatory activity and innate immunity. Thus, at low concentrations, PMX-53 could block inflammation by acting as a CD88 antagonist, but it can promote innate immunity at higher concentrations, through mimicking the actions of defensins on mast cell activation (Subramanian et al., 2011a , Subramanian et al., 2011b , Subramanian et al., 2013 .
4.5.ˇ-defensins activate human mast cells via MRGX2
Human ␤-defensins can activate human mast cells via MRGX2. Both PT-sensitive and insensitive signaling pathways most likely involving G ␣q and G ␣i are involved in the degranulation of mast cells. In contrast, murine mast cells are resistant to ␤-defensins for degranulation, and this reflects the absence of MRGX2 in these cells. In addition, silencing the expression of MRGX2 in human mast cells could inhibit ␤-defensin-induced degranulation, but could not influnecne the anaphylatoxin C3a-induced response. Furthermore, ectopic expression of MRGX2 in RBL-2H3 and murine BMMCs rendered these cells responsive to ␤-defensins for degranulation (Niyonsaba et al., 2003 , Chen et al., 2007 , Niyonsaba et al., 2010 , Subramanian et al., 2013 .
The function of MRGX2 and further research clue
Recently, MRGX receptors have been found in the macaque (Zhang et al., 2005) . As rhesus monkey is a commonly used animal model for experimental biology and drug discovery, Zhang (Zhang et al., 2005) cloned and pharmacologically analyzed rhesus monkey MRGX receptor counterparts for each of the known human MRGX receptors, and found that they are functionally as well as structurally similar to the known human MRGX receptors. These data suggest that the rhesus monkey may be a suitable animal model for exploring the physiological roles of MRGX receptors. Most of the human and rhesus MRGX receptor subtypes displayed high constitutive activity in a cellular proliferation assay.
To investigate the downstream signaling of MRGX2, the increase or decrease of intracellular cAMP was monitored in response to MRGX2 activation. In MRGX2-expressing cells, CST stimulated an increase in intracellular Ca 2+ but did not show influence on cAMP levels. These results taken together indicate that this receptor functions via a G q associated mechanism. The identification of MRGX2 as the first human CST-preferred receptor, together with the colocalization of the receptor and ligand in the DRG, should promote investigation into the role of CST and its receptor in nociception. MRGA1, MRGA4, MRGX1 and a rat MRG receptor, all of which share 45-65% amino acid identity with MRGX2, exhibit overlapping expression within small diameter fibers of the DRG neurons. The structure-activity relationships and rank order of potency of their respective ligands are distinct, suggesting the involvement of the Mrg family in subtle regulation and fine-tuning of nociceptive responses.
Cortistatin-14 (CST-14) is a high affinity ligand for the orphan receptor MRGX2 and has been shown to play a role in the induction of slow wave sleep, inhibition of locomotor activity and cell proliferation. Immuno-histochemical studies show moderate levels of MRGX2 expression in subsets of neurons in the CA2, CA3, and CA4 regions of the hippocampus, suggesting that it is highly related with CST. Quantitative PCR studies show CST to have a broad tissue distribution as compared with the limited expression of MrgX2. This is not unexpected as a number of the diverse actions of CST have been shown to be mediated via interactions with the widely distributed somatostatin family of receptors.
Human mast cell line LAD2 and CD34 + cell-derived primary mast cells can express MRGX2, responded to LL-37, and finally resuled in Ca 2+ mobilization and degranulation. In contrast, an immature human mast cell line HMC-1 that lacks functional MRGX2 did not respond to LL-37. After MrgX2 is knocked down, LAD2 mast cell line and primary CD34 + cell-derived mast cells show a decrease in the LL-37-induced degranulation. Furthermore, mast cell lines stably expressing MRGX2 responded to LL-37 for chemotaxis, degranulation, and CCL4 production. Nevertheless, MRGX2 was resistant to the phosphorylation, desensitization, and internalization induced by LL-37. In addition, knockdown of the GPCR kinases (GRK2 and GRK3) had no effect on LL-37-induced mast cell degranulation. This study identified MRGX2 as a novel GPCR for the antibacterial peptide LL-37, and unlike most GPCR, it is resistant to agonist-induced receptor phosphorylation, desensitization, and internalization.
Conclusions
MrgX2 has undergone adaptive changes along the human evolution, and this was probably caused by Darwinian positive selection. In addition, MrgX2 along with Mrg gene family has undergone strong Darwinian positive selection in mammalian species, therefore, an implication of its involvement in the adaptive evolution of the pain-perception-related nervous system and immune system.
Bio-informatics and tissue distribution analysis can be used to prioritize those orphan receptors with potential therapeutic relevance. A "reverse pharmacology" method can be used to identify cognate and surrogate ligands. MrgX2 is gene that is primarily expressed in human DRGs, TRGs and mast cells. MRGX2 can interact with various peptides, including substance P, vasoactive intestinal peptide, CST, PAMP, LL-37, PMX-53, and ␤-defensins for multiple functions such as nociception and immune defense. However, the detailed physiological functions of the MRGX2 receptors and the underlying mechanisms of signal transduction still need to be explored.
